UAB "Novo Nordisk Pharma" Finance - revenue, profit
EBITDA margin (%)
Enjoy unlimited use
with Freemium unlimitedEBIT margin (%)
Enjoy unlimited use
with Freemium unlimited| Indicator |
|---|
| Turnover (€) |
| Sales per employee (€) |
| Profit before tax (€) |
| Net Profit (€) |
| Profit per employee (€) |
| Total profitability (%) |
| Net profitability (%) |
| Equity (€) |
| Amounts Payable And Liabilities (€) |
| Non-current Assets (€) |
| CurrentAssets (€) |
| Working capital requirement |
| Debt-to-equity ratio |
| EBITDA margin (%) |
| EBITDA (€) |
| EBIT margin (%) |
| EBIT (€) |
| 2023 |
|---|
| 21,820,183 |
| 935,284 |
| 912,567 |
| 752,671 |
| 32,262 |
| 12.00 |
| 3.45 |
| 1,835,713 |
| 4,375,007 |
| 35,460 |
| 6,332,559 |
| 2024 |
|---|
| 28,628,471 |
| 1,075,046 |
| 1,223,040 |
| 1,010,395 |
| 37,942 |
| 16.08 |
| 3.53 |
| 2,846,108 |
| 8,494,236 |
| 66,940 |
| 11,429,793 |
| 2025 |
|---|
| 40,026,604 |
| 1,356,834 |
| 1,604,359 |
| 1,270,136 |
| 43,055 |
| 12.17 |
| 3.17 |
| 3,116,244 |
| 11,142,413 |
| 63,693 |
| 14,286,453 |
Enjoy unlimited use
with Freemium unlimited| 2025 |
|---|
| 40,026,604 |
| 1,356,834 |
| 1,604,359 |
| 1,270,136 |
| 43,055 |
| 12.17 |
| 3.17 |
| 3,116,244 |
| 11,142,413 |
| 63,693 |
| 14,286,453 |
Enjoy unlimited use
with Freemium unlimitedTurnover (€)
2025
Turnover (€)
40,026,604 €40 % *
Sales per employee (€)
1,356,834 €26 % *
Profit before tax (€)
1,604,359 €31 % *
Net Profit (€)
1,270,136 €26 % *
Profit per employee (€)
43,055 €13 % *
Total profitability (%)
12.17 %-24.32 % *
Net profitability (%)
3.17 %-10.20 % *
Equity (€)
3,116,244 €9 % *
Amounts Payable And Liabilities (€)
11,142,413 €31 % *
Non-current Assets (€)
63,693 €-5 % *
CurrentAssets (€)
14,286,453 €25 % *
